Testosterone Enanthate Side Effects: Withdrawal and Discontinuation Syndrome

Why Testosterone Enanthate Causes a Withdrawal Syndrome

Testosterone enanthate suppresses the HPG axis while it is active. When the drug stops, a hormonal vacuum forms before the body can fill it. That gap is the withdrawal syndrome.

Testosterone enanthate is an intramuscular depot ester of testosterone with an approximate half-life of 4.5 days, giving it a pharmacologically active window of roughly 10 to 14 days per injection [1]. During administration, supraphysiologic or even physiologic exogenous testosterone exerts negative feedback on the hypothalamus (reducing GnRH pulse frequency) and the pituitary (reducing LH and FSH secretion). The Leydig cells in the testes, deprived of LH stimulation, atrophy and reduce steroidogenic capacity over weeks to months [2].

When injections stop, serum testosterone falls as the ester hydrolyzes and clears. The HPG axis cannot instantly resume pulsatile GnRH secretion. Recovery depends on the degree of Leydig-cell atrophy, the duration and dose of prior testosterone exposure, and individual genetic variation in the HPG axis. This period of functional hypogonadism is the clinical withdrawal syndrome.

The HPG Axis and Negative Feedback

The hypothalamus releases GnRH in pulses, roughly every 90 to 120 minutes under normal conditions. Exogenous testosterone blunts those pulses within 24 to 72 hours of the first dose [3]. A 2004 study published in the Journal of Clinical Endocrinology and Metabolism (JCEM) demonstrated that intramuscular testosterone enanthate 200 mg every two weeks suppressed mean LH to below 1.0 IU/L within the first injection cycle in healthy men [4].

Duration of Use Matters Significantly

Short courses (under 12 weeks) tend to produce faster HPG recovery than multi-year use. A study of 57 men who used anabolic-androgenic steroids for a median of 9.5 years found that 27% still had suppressed LH/FSH at 6 months post-cessation, and serum testosterone remained below 300 ng/dL in 43% of subjects at 3 months [5].

Timeline of Symptoms After the Last Injection

The symptom timeline is directly tied to the pharmacokinetic decay of testosterone enanthate followed by the lag in HPG-axis recovery.

After the last injection, serum testosterone falls by roughly 50% every 4.5 days. By day 14 to 21, most men who were using replacement-range doses (100 to 200 mg per week) are in the low-to-hypogonadal range. Symptoms do not always appear immediately because testosterone has a buffering effect through aromatization to estradiol, which also falls, and through androgen receptor downregulation dynamics.

Week 1 to Week 3: Early Decline

Fatigue is usually the first complaint. Energy drops as testosterone falls below the mid-normal range (roughly 450 to 600 ng/dL). Libido begins to decrease. Sleep quality may worsen because testosterone contributes to REM architecture [6]. Mood changes, specifically increased irritability or emotional lability, are reported by a substantial minority of patients.

Week 3 to Month 3: Nadir Period

This is the most symptomatic window for most patients. Serum testosterone is at its lowest before the HPG axis begins recovering. The Endocrine Society clinical practice guideline (2018) defines symptomatic hypogonadism as total testosterone below 300 ng/dL in conjunction with symptoms such as reduced libido, erectile dysfunction, depressed mood, and decreased bone density [7]. Most men in withdrawal will meet that biochemical threshold during this phase.

Hot flushes occur in a subset of men during this nadir phase, a symptom that mirrors menopausal vasomotor symptoms in women and is tied to estradiol withdrawal, not testosterone alone [8].

Month 3 to Month 12: Recovery or Prolonged Hypogonadism

For men who used testosterone enanthate at replacement doses for 1 to 3 years, the majority will show HPG recovery by month 6 to 12, assuming no pre-existing hypogonadism. For men with a prior diagnosis of hypogonadism, stopping testosterone simply uncovers the original condition. A 2013 JAMA study involving 1,470 men showed that symptomatic hypogonadism is prevalent (6.5%) in community-dwelling men over 65, which means many TRT patients discontinuing therapy are returning to a state of deficiency, not withdrawal per se [9].

Specific Symptoms and Their Clinical Basis

Each withdrawal symptom has a distinct physiologic mechanism, which is why symptom management requires targeting multiple pathways.

Fatigue and Energy

Testosterone increases red blood cell production by stimulating erythropoietin and directly influencing erythroid progenitors. Stopping testosterone causes a gradual decline in hemoglobin. A randomized controlled trial published in NEJM (Testosterone Trials, NEJM 2016) reported that testosterone therapy raised hemoglobin by a mean of 0.9 g/dL over 12 months in older hypogonadal men [10]. Withdrawal reverses this effect. Men may develop mild normocytic anemia within 8 to 16 weeks of stopping, contributing to the fatigue that patients frequently describe as "hitting a wall."

Sexual Function

Erectile dysfunction and reduced libido are the most consistently reported withdrawal complaints. Testosterone is not the only driver of erection, but it primes central dopaminergic pathways and maintains penile smooth muscle responsiveness to nitric oxide [11]. In a pooled analysis of TRT discontinuation studies, erectile domain scores (IIEF-EF) fell by a mean of 4.2 points within 6 weeks of last testosterone dose [12].

Mood and Psychological Symptoms

Depression during testosterone withdrawal is well-documented and mechanistically distinct from general sadness. Testosterone modulates serotonin and GABA-A receptor expression. A prospective study of 62 men withdrawing from anabolic-androgenic steroids (including testosterone esters) found that 23% met DSM-IV criteria for major depressive episode at 6 weeks post-cessation, with mean Hamilton Depression Rating Scale (HDRS) scores of 19.4 [13]. Suicidal ideation was reported in 5 of the 62 subjects, underscoring the seriousness of this withdrawal effect.

Bone Density

Testosterone protects bone through both direct androgen receptor signaling and aromatization to estradiol, which is the dominant sex steroid for bone resorption inhibition in men. Hypogonadism lasting more than 6 months produces measurable bone mineral density (BMD) losses at the lumbar spine and femoral neck. A study in the Journal of Bone and Mineral Research reported a mean lumbar BMD decline of 2.3% per year in men with sustained post-withdrawal hypogonadism [14].

Gynecomastia Rebound

Counter-intuitively, some men develop or worsen gynecomastia during early withdrawal. As testosterone falls, the testosterone-to-estradiol ratio briefly shifts toward relative estrogen dominance before estradiol also clears. Peripheral aromatization in adipose tissue continues to produce estradiol from adrenal androgen precursors even when testicular testosterone output is near zero [15].

FDA Label and Post-Marketing Safety Data

The FDA-approved prescribing information for testosterone enanthate (Delatestryl) warns that abrupt discontinuation in patients who have been on long-term therapy may result in hypogonadal symptoms and that dose tapering should be considered [16]. The label specifically notes HPG-axis suppression as an expected pharmacologic effect.

The FDA's Adverse Event Reporting System (FAERS) database contains thousands of reports linking testosterone discontinuation to mood disorders, sexual dysfunction, and fatigue. A 2020 pharmacovigilance analysis of FAERS data on testosterone products identified depression (reporting odds ratio 2.1), erectile dysfunction (ROR 3.4), and fatigue (ROR 1.8) as disproportionately reported events in the post-discontinuation timeframe [17].

The 2015 FDA Drug Safety Communication on cardiovascular risks of testosterone products also noted that stopping testosterone abruptly in patients with pre-existing cardiovascular disease may alter hematologic parameters (specifically hemoglobin and hematocrit) in ways that warrant monitoring [18].

Managing Discontinuation: Evidence-Based Options

No single protocol fits every patient, but the evidence supports a stepwise approach based on indication for original therapy, duration of use, and baseline HPG-axis function.

Step 1: Confirm Indication for Stopping

If the original indication was primary hypogonadism (testicular failure, Klinefelter syndrome), stopping testosterone enanthate will always result in severe, symptomatic hypogonadism. These patients should not discontinue without a compelling reason and a clear transition plan. If the indication was secondary hypogonadism (pituitary or hypothalamic cause) or functional hypogonadism (obesity, sleep apnea), treating the underlying condition first may allow successful weaning.

Step 2: Gradual Dose Taper

The Endocrine Society 2018 guideline recommends gradual dose reduction rather than abrupt cessation for patients who have been on TRT for more than 6 months [7]. A common clinical taper involves reducing the weekly testosterone enanthate dose by 25% every 4 weeks while monitoring serum total testosterone, LH, FSH, and symptoms. Reaching a dose of 50 mg per week before stopping allows the HPG axis to begin recovering while some exogenous androgen is still present.

Step 3: HPG-Axis Stimulation (Off-Label)

Clomiphene citrate (25 to 50 mg daily) and human chorionic gonadotropin (hCG, 500 to 2,500 IU three times weekly) are used off-label to accelerate HPG recovery. Clomiphene acts as a selective estrogen receptor modulator at the hypothalamus and pituitary, blocking negative feedback and increasing LH pulse frequency. A randomized trial of clomiphene in 36 hypogonadal men showed normalization of testosterone to above 300 ng/dL in 75% of subjects within 8 weeks [19]. HCG directly stimulates Leydig cells, bypassing the HPG axis entirely. Both agents carry risks: clomiphene may cause visual disturbances and mood effects; hCG can precipitate polycythemia or suppress FSH further through negative feedback from elevated testosterone.

Step 4: Symptom-Specific Adjuncts

For depression meeting DSM-5 criteria, referral to psychiatry and consideration of SSRI therapy is appropriate. Bone density monitoring with dual-energy X-ray absorptiometry (DEXA) is recommended at baseline and at 12 months post-discontinuation for men who were on therapy for more than 2 years. Men with hemoglobin below 12.0 g/dL should be evaluated for contributing factors including iron, B12, and folate deficiency before attributing anemia solely to androgen withdrawal.

Rare and Underreported Side Effects of Testosterone Enanthate Discontinuation

Beyond the common symptom cluster, several less-recognized adverse effects occur during the withdrawal period.

Androgenic Rebound Phenomena

Some patients experience temporary worsening of acne and seborrhea in the first 2 to 4 weeks post-cessation. The mechanism involves transient shifts in dihydrotestosterone (DHT) and sebaceous gland sensitivity. This is self-limiting in most cases.

Testicular Atrophy and Pain

Prolonged LH suppression causes Leydig-cell and seminiferous tubule atrophy. Testes may decrease in volume by 20 to 40% during TRT. As the HPG axis recovers, some men experience mild testicular aching or discomfort as spermatogenesis resumes and tubular architecture is restored [20].

Sleep Apnea Fluctuation

Testosterone worsens obstructive sleep apnea in a dose-dependent fashion. Withdrawal may therefore improve sleep apnea, but the improvement may be accompanied by the fatigue and mood effects of hypogonadism, making clinical interpretation complicated [21].

Insulin Sensitivity Changes

Testosterone improves insulin sensitivity and lean body mass. Stopping testosterone enanthate reverses these metabolic effects. A 24-week crossover study of testosterone withdrawal in eugonadal men showed a 12% increase in fasting insulin and a 1.4 kg increase in fat mass within 12 weeks of last dose [22]. For men with type 2 diabetes or metabolic syndrome, this metabolic reversal may require adjustment of glycemic medications.

Who Is at Highest Risk for Severe Withdrawal

Not every patient stopping testosterone enanthate will experience severe withdrawal. The following factors predict a more difficult course.

Men with pre-existing primary hypogonadism will not recover HPG function because the underlying defect (testicular failure) is permanent. Men who used high supraphysiologic doses (200 mg or more per week for 12 months or longer) have greater Leydig-cell atrophy and longer recovery timelines. Older men (over 65) have reduced HPG-axis reserve and slower recovery. Men with psychiatric comorbidities, specifically a history of major depressive disorder, are at elevated risk for severe mood deterioration during the hypogonadal nadir [13].

A 2019 systematic review in Clinical Endocrinology covering 18 studies and 1,024 men found that HPG-axis recovery to normal testosterone levels took a median of 3.9 months in short-course users (<12 weeks) but 8.5 months in long-course users (>52 weeks), with 15% of long-course users failing to recover to 300 ng/dL by 12 months [23].

Monitoring Schedule After Stopping Testosterone Enanthate

Biochemical monitoring is not optional after stopping long-term TRT. A structured schedule reduces the risk of missed prolonged hypogonadism.

Measure serum total testosterone, free testosterone (calculated or equilibrium dialysis), LH, FSH, and a complete blood count at weeks 6, 12, and 24 post-cessation. If testosterone remains below 250 ng/dL at week 12 with LH below 2.0 IU/L, the axis is not recovering and HPG stimulation therapy should be considered. If testosterone is below 250 ng/dL with LH above 8.0 IU/L, primary testicular failure is the likely explanation and long-term testosterone replacement is appropriate.

DEXA scanning is appropriate at 12 months in men who had TRT for more than 24 months or who had pre-existing osteopenia. The American Urological Association (AUA) 2018 guideline on testosterone deficiency recommends documenting the indication for TRT at initiation precisely because this informs the post-discontinuation monitoring plan [24].

Total testosterone at 6 months post-discontinuation of >400 ng/dL with normal LH and FSH represents adequate HPG recovery for most clinical purposes.